Home › Compare › CTRGF vs ABBV
CTRGF yields 2.44% · ABBV yields 3.06%● Live data
📍 CTRGF pulled ahead of the other in Year 4
Combined, CTRGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CTRGF + ABBV for your $10,000?
Country Garden Services Holdings Company Limited, an investment holding company, provides property management services to property owners, residents, and property developers in the People's Republic of China. It offers security, cleaning, green landscaping, gardening, repair and maintenance, and other services. The company's property management portfolio includes residential properties, commercial properties, office buildings, industrial parks, multi-purpose complexes, government buildings, hospitals, and schools, as well as other public facilities, such as airport terminals, highway service stations, scenic areas, and other non-residential properties. As of December 31, 2021, it managed 6,046 property projects. The company also provides community value-added services comprising home, home decoration, community media, value added innovation, real estate brokerage, and community area services. In addition, it offers consultancy services to property developers for the management of their pre-sale activities, as well as consultancy services for properties managed by other property management companies; and cleaning, greening, repair, and maintenance services to property developers at the pre-delivery stage. Further, the company provides sales and leasing agency services of unsold parking spaces and properties; heat supply, city, and city media services; and e-commerce services. The company was founded in 1992 and is headquartered in Foshan, the People's Republic of China.
Full CTRGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.